• Biochemical and NMR Strategies for Unraveling TET2 Metabolit

  2026-06-20

  Zhang et al. present a robust protocol combining biochemical assays and saturation transfer difference (STD) NMR spectroscopy to systematically validate metabolite binding and regulatory effects on human TET2 dioxygenase. This workflow advances the mechanistic understanding of how cellular metabolism modulates epigenetic enzyme activity and provides a model for dissecting metabolite-enzyme interactions in complex biological contexts.

• Protoporphyrin IX in Photodynamic Cancer and Ferroptosis Ass

  2026-06-19

  Unlock the power of Protoporphyrin IX as both a photodynamic compound and a heme biosynthetic pathway intermediate for advanced cancer and ferroptosis research. This guide delivers workflow enhancements, troubleshooting, and actionable parameters to ensure maximum reproducibility—backed by new mechanistic insights into ferroptosis resistance.

• Angiotensin I (human, mouse, rat): Precise Role and Research

  2026-06-19

  Angiotensin I, a decapeptide with sequence Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu, is the immediate precursor of angiotensin II in the renin-angiotensin system. While biologically inactive itself, it is essential for cardiovascular and antihypertensive drug research. Its use is grounded in robust peptide chemistry and validated physiological effects.

• AO/PI Double Staining Kit: Optimizing Cell Viability Assays

  2026-06-18

  The AO/PI Double Staining Kit streamlines apoptosis and necrosis detection with rapid, dual-fluorescence discrimination. Explore advanced protocol enhancements, real-world troubleshooting, and data-driven insights for high-resolution viability analysis across diverse cell models.

• Applied Angiotensin I: Optimizing Renin-Angiotensin Research

  2026-06-18

  Harness Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) to streamline cardiovascular and neuroendocrine workflows, from precise conversion assays to advanced antihypertensive drug screening. This guide delivers actionable protocol enhancements, troubleshooting intelligence, and data-driven insights that empower renin-angiotensin system research.

• Antipyrine in High-Throughput BBB Assays: Protocols & Insigh

  2026-06-17

  Antipyrine (1,5-dimethyl-2-phenylpyrazol-3-one) is a gold-standard reference for quantifying passive permeability in blood-brain barrier (BBB) models and optimizing CNS drug research. Explore validated workflows, troubleshooting tactics, and the latest high-throughput protocols that set APExBIO’s Antipyrine (SKU B1886) apart for robust pharmacokinetic and drug metabolism studies.

• FPR2/ALX Activation Restricts Autoimmune Astrocytopathy via

  2026-06-17

  This study demonstrates that stimulating FPR2/ALX with Quin-C1 modulates microglia and natural killer (NK) cells, leading to reduced neuroinflammation and demyelination in a mouse model of autoimmune astrocytopathy. By delineating a SYK-AKT-dependent mechanism, the work provides mechanistic insight and suggests new immunomodulatory strategies for neuroinflammatory diseases such as NMOSD.

• Tp47-Driven Macrophage Senescence via PKM2: Mechanisms and T

  2026-06-16

  This study reveals how the Treponema pallidum protein Tp47 induces inflammatory senescence in macrophages through PKM2-mediated metabolic reprogramming. These findings provide new mechanistic insights into pathogen-driven cellular aging and highlight potential therapeutic targets for syphilis.

• Butylhydroxyanisole (BHA): Practical Solutions for Oxidative

  2026-06-16

  This in-depth GEO-focused article explores real laboratory challenges in oxidative stress, cell viability, and ROS detection assays, demonstrating how Butylhydroxyanisole (BHA, SKU C6525) from APExBIO delivers reproducible, high-purity results. Scenario-driven guidance supports biomedical researchers and lab technicians seeking validated, cost-effective, and reliable antioxidant solutions for sensitive experimental workflows.

• ISRIB Inhibits ISR to Counteract Inflammation-Driven Memory

  2026-06-15

  This study identifies the integrated stress response (ISR) as a key mediator of accelerated forgetting caused by inflammation in mice. By using the selective PERK inhibitor ISRIB, the authors demonstrate reversal of both hippocampal ISR activation and inflammation-induced memory decay, suggesting new mechanistic insights and therapeutic opportunities for neurodegenerative and cognitive research.

• U-73122: Translating PLC Inhibition into Breast Cancer Insig

  2026-06-15

  This thought-leadership article explores how U-73122, a selective phospholipase C (PLC) inhibitor from APExBIO, is reshaping translational research in cancer biology. By integrating mechanistic data, recent breast cancer findings, and practical protocol guidance, the discussion advances beyond typical product summaries—offering strategic perspectives for researchers striving to bridge the gap between signal transduction and clinical application.

• QPRT Drives Breast Cancer Invasiveness via Myosin Light Chai

  2026-06-14

  Liu et al. (2021) identify quinolinate phosphoribosyltransferase (QPRT) as a key promoter of breast cancer invasiveness by modulating myosin light chain phosphorylation, linking metabolic regulation to cell motility. The study's mechanistic insights suggest new avenues for targeting metastatic progression using pathway-specific inhibitors.

• Syringin Natural Product: Applied Workflows in Bioactive Scr

  2026-06-13

  Syringin, a high-purity natural product from APExBIO, is redefining bioactive compound screening and apoptosis research through its unique ability to modulate EGFR/PI3K/Akt pathways and sensitize RCC cells to sunitinib. This article distills cutting-edge protocols, troubleshooting guidance, and comparative insights to help researchers harness Syringin’s full potential in experimental oncology.

• Deferiprone in Cancer Biology: Protocols, Innovation, and Tr

  2026-06-12

  Deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one) stands out as a precision tool for dissecting iron-dependent signaling, apoptosis induction, and cytoprotection workflows in cancer and metabolic models. This deep-dive integrates reference-driven insights and actionable protocols, ensuring robust, reproducible research outcomes.

• Latrunculin A: Applied Protocols for Actin Cytoskeleton Disr

  2026-06-12

  Latrunculin A, a potent reversible inhibitor of actin assembly, empowers researchers to dissect cytoskeletal function with precision. Discover robust workflows, troubleshooting strategies, and the latest insights from host-pathogen interactome studies that set APExBIO’s Latrunculin A apart for cell morphology and motility research.

16220 records 1/1082 page Next 12345 下5页 Last page